Letter from the Editor

Dear Reader,

At the annual meeting of the European Hematology Association held on 14-17 June 2018 in Stockholm, Sweden, nearly 12,000 participants from all over the world were informed on new developments in different areas of interest.

Basic scientists, translational haematologists, clinicians, patients, pharmacists, employees of pharmaceutical companies, and others interested in haematology attended this exciting meeting. In this report, we made a selection of interesting presentations out of the numerous talks that were given on myeloid and lymphoid malignancies, multiple myeloma, stem cell transplantation, benign haematology topics, and paediatric haematology. Many new treatment options and strategies are emerging, creating a lot of possibilities for haematology patients. Targeted treatments and immunotherapy are now rapidly evolving and are already available or will soon become available. We hope that this report will give you some insight into the recent developments in the field of haematology.

Best regards,

Gert Ossenkoppele

 

Biography
Professor Gert Ossenkoppele was appointed in 2003 as professor of Hematology at the VU University Medical Center in Amsterdam. Gert Ossenkoppele has authored over 390 publications in peer-reviewed journals and is an invited speaker at many international scientific meetings. His research interests are mainly translational and include the (stem cell) biology of AML, leukemic stem cell target discovery, immunotherapy, and measurable residual disease (MRD) detection using flow cytometry to inform treatment of AML. He is the PI of various clinical trials in myeloid malignancies. He chairs the AML working party of HOVON (Dutch-Belgian Hematology Trial Group) and is appointed as vice-chair of the HOVON Executive Board. He is a lead participant of the AML Work package of the European LeukemiaNet (ELN) as well as a board member of the ELN foundation. He is recently appointed as chair of the EHA Educational Committee. He chairs the AML Scientific working group of EHA, and he is chair of the Global and EU steering committee of the AMLGlobalPortal an educational portal for hematologists (www.amlglobalportal.com).

Conflict of Interest Statement:

Prof. Ossenkoppele is consultant for Novartis and BMS.



Posted on 28 June, 201823 March, 2021